battle of glp-1 delivery technologies Pharma Giants Bet on Next-Generation

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

GLP-1 receptor agonists have shown cardiovascular benefits beyond weight loss, including potential improvements in cholesterol profiles

New research suggests GLP-1 medications may influence osteoarthritis beyond weight loss

The cravings eased, the intense hunger episodes stopped, and I no longer felt the urge to drink wine before bed

Clinical trials show average weight loss can reach 15-20% of body weight - SURMOUNT-1 and STEP-1 trials confirmed this in thousands of patients

Contact us here.